{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["HepG2", "MCF-7", "MTT assay", "QSAR", "VEGFR-2", "apoptosis", "benzoquinazolines", "docking study"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": [], "GeneralNote": [], "PMID": "33333992", "DateCompleted": {"Year": "2024", "Month": "07", "Day": "24"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "26"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "12", "Day": "15"}], "Language": ["eng"], "ELocationID": ["5944", "10.3390/molecules25245944"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "25", "Issue": "24", "PubDate": {"Year": "2020", "Month": "Dec", "Day": "15"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Antiproliferative and Antiangiogenic Properties of New VEGFR-2-targeting 2-thioxobenzo[<i>g</i>]quinazoline Derivatives (In Vitro).", "Abstract": {"AbstractText": ["A series of 3-ethyl(methyl)-2-thioxo-2,3-dihydrobenzo[<i>g</i>]quinazolines (<b>1</b>-<b>17</b>) were synthesized, characterized, and evaluated in vitro for their antiangiogenesis VEGFR-2-targeting, antiproliferative, and antiapoptotic activities against breast MCF-7 and liver HepG2 cells. Flow cytometry was used to determine cancer-cell cycle distributions, and apoptosis was detected using annexin-V-FITC (V) and propidium iodide (PI) dyes. Fluorescence microscopy, in combination with Hoechst staining was used to detect DNA fragmentation. Most of the tested benzo[<i>g</i>]quinazolines demonstrated promising activity (IC<sub>50</sub> = 8.8 \u00b1 0.5-10.9 \u00b1 0.9 \u03bcM) and (IC<sub>50</sub> = 26.0 \u00b1 2.5-40.4 \u00b1 4.1 \u03bcM) against MCF-7 and HepG2, respectively. Doxorubicin was used as a reference drug. Compounds <b>13</b>-<b>15</b> showed the highest activity against both cancer cell lines. Differential effects were detected by cell-cycle analysis, indicating similarities in the actions of <b>13</b> and <b>14</b> against both MCF7 and HepG2, involving the targeting of G1 and S phases, respectively. Compound <b>15</b> showed similar indices against both cells, indicating that its cytotoxicity toward the examined cancer cells could be unselective. Interestingly, <b>14</b> and <b>15</b> showed the highest apoptosis (30.76% and 25.30%, respectively) against MCF-7. The DNA fragmentation results agreed well with the apoptosis detected by flow cytometry. In terms of antiangiogenesis activity, as derived from VEGFR-2 inhibition, <b>13</b> and <b>15</b> were comparable to sorafenib and effected 1.5- and 1.4-fold inhibition relative to the standard sorafenib. A docking study was conducted to investigate the interaction between the synthesized benzo[<i>g</i>]quinazolines and the ATP-binding site within the catalytic domain of VEGFR-2."]}, "AuthorList": [{"Identifier": ["0000-0002-7092-7544"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia."}], "LastName": "Abuelizz", "ForeName": "Hatem A", "Initials": "HA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Tanning Materials and Leather Technology, National Research Centre, 33 El-Bohouth St. (Former El-Tahrir St.), Dokki, Cairo 12622, Egypt."}], "LastName": "Marzouk", "ForeName": "Mohamed", "Initials": "M"}, {"Identifier": ["0000-0002-0445-1357"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Chemistry, Faculty of Science and Technology, El-Neelain University, P.O. Box 12702, Khartoum 11121, Sudan."}], "LastName": "Bakheit", "ForeName": "Ahmed H", "Initials": "AH"}, {"Identifier": ["0000-0002-3970-2371"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Tanning Materials and Leather Technology, National Research Centre, 33 El-Bohouth St. (Former El-Tahrir St.), Dokki, Cairo 12622, Egypt."}], "LastName": "Awad", "ForeName": "Hanem M", "Initials": "HM"}, {"Identifier": ["0000-0002-7370-0142"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biology Unit, Central Laboratory for Pharmaceutical and Drug Industries Research Division, Chemistry of Medicinal Plants Department, National Research Centre, El Bohouth St. 33, Dokki, Cairo 12622, Egypt."}], "LastName": "Soltan", "ForeName": "Maha M", "Initials": "MM"}, {"Identifier": ["0000-0003-4377-5239"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, Drug Exploration and Development Chair (DEDC), College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Peptide Chemistry Department, Chemical Industries Research Division, National Research Centre, 33 El-Bohouth St. (Former El-Tahrir St.), Dokki, Cairo 12622, Egypt."}], "LastName": "Naglah", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia."}], "LastName": "Al-Salahi", "ForeName": "Rashad", "Initials": "R"}], "GrantList": [{"GrantID": "RG-1435-068", "Agency": "Deanship of Scientific Research, King Saud University", "Country": ""}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "Vascular Endothelial Growth Factor Receptor-2"}, {"RegistryNumber": "0", "NameOfSubstance": "Angiogenesis Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Quinazolines"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "KDR protein, human"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "Vascular Endothelial Growth Factor Receptor-2"}, {"QualifierName": ["pharmacology", "chemistry", "chemical synthesis"], "DescriptorName": "Angiogenesis Inhibitors"}, {"QualifierName": ["pharmacology", "chemistry", "chemical synthesis"], "DescriptorName": "Quinazolines"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": [], "DescriptorName": "MCF-7 Cells"}, {"QualifierName": [], "DescriptorName": "Hep G2 Cells"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": ["pharmacology", "chemistry", "chemical synthesis"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Cycle"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Viallard C., Larriv\u00e9e B. Tumor angiogenesis and vascular normalization: Alternative therapeutic targets. Angiogenesis. 2017;20:409\u2013426. doi: 10.1007/s10456-017-9562-9.", "ArticleIdList": ["10.1007/s10456-017-9562-9", "28660302"]}, {"Citation": "El-GazzarRania M.G., El-HazekNashwa R.M., Zaher N.H., El-Ghazaly M.A. Design and synthesis of novel pyridazinoquinazoline derivatives as potent VEGFR-2 inhibitors: In vitro and in vivo study. Bioorg. Chem. 2019;92:103251. doi: 10.1016/j.bioorg.2019.103251.", "ArticleIdList": ["10.1016/j.bioorg.2019.103251", "31525526"]}, {"Citation": "Aziz M.A., Serya R.A., Lasheen D.S., Abdel-Aziz A.K., Esmat A., Mansour A.M., Singab A.N., Abouzid A.M. Discovery of potent VEGFR-2 inhibitors based on furopyrimidine and thienopyrimidne scaffolds as cancer targeting agents. Sci. Rep. 2016;15:24460. doi: 10.1038/srep24460.", "ArticleIdList": ["10.1038/srep24460", "PMC4832243", "27080011"]}, {"Citation": "Shi L., Zhou J., Wu J., Shen Y., Li X. Anti-angiogenic therapy: Strategies to develop potent VEGFR-2 tyrosine kinase inhibitors and future prospect. Curr. Med. Chem. 2016;23:1000\u20131040. doi: 10.2174/0929867323666160210130426.", "ArticleIdList": ["10.2174/0929867323666160210130426", "26860998"]}, {"Citation": "Modi S.J., Kulkarni V.M. Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR inhibitors. Med. Chem. Perspect. Med. Drug Discov. 2019;2:100009. doi: 10.1016/j.medidd.2019.100009.", "ArticleIdList": ["10.1016/j.medidd.2019.100009"]}, {"Citation": "Liu Y., Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2006;2:358\u2013364. doi: 10.1038/nchembio799.", "ArticleIdList": ["10.1038/nchembio799", "16783341"]}, {"Citation": "Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA. 2005;102:7665\u20137670. doi: 10.1073/pnas.0502860102.", "ArticleIdList": ["10.1073/pnas.0502860102", "PMC1129023", "15897464"]}, {"Citation": "Ghorab M.M., Alsaid M.S., Soliman A.M., Ragab F.A. VEGFR-2 inhibitors and apoptosis inducers: Synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety. J. Enzyme Inhib. Med. Chem. 2017;32:893\u2013907. doi: 10.1080/14756366.2017.1334650.", "ArticleIdList": ["10.1080/14756366.2017.1334650", "PMC6445170", "28661197"]}, {"Citation": "Huang L., Huang Z., Bai Z., Xie R., Sun L., Lin K. Development and strategies of VEGFR-2/KDR inhibitors. Future Med. Chem. 2012;4:1839\u20131852. doi: 10.4155/fmc.12.121.", "ArticleIdList": ["10.4155/fmc.12.121", "23043480"]}, {"Citation": "Kornev A.P., Haste N.M., Taylor S.S., Ten Eyck L.F. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc. Natl. Acad. Sci. USA. 2006;103:17783\u201317788. doi: 10.1073/pnas.0607656103.", "ArticleIdList": ["10.1073/pnas.0607656103", "PMC1693824", "17095602"]}, {"Citation": "Al-Salahi R., Abuelizz H., Eldib R., Wadi M., Alotaibi M., Marzouk M. Antimicrobial activity of newly synthesized 2-methylthio-benzo[g][1,2,4]-triazolo[1,5-a]quinazolines. Med. Chem. 2016;12:760\u2013766. doi: 10.2174/1573406412666160502155106.", "ArticleIdList": ["10.2174/1573406412666160502155106", "27140181"]}, {"Citation": "Al-Salahi R., Abuelizz H., Ghabbour H., Eldib R., Marzouk M. Molecular Docking and Antiviral Evaluation of 2-Thioxo-benzo[g]quinazolin-4(3H)-one derivatives. Chem. Cent. J. 2016;10:1\u20137. doi: 10.1186/s13065-016-0168-x.", "ArticleIdList": ["10.1186/s13065-016-0168-x", "PMC4837545", "27099618"]}, {"Citation": "Al-Salahi R., El-dib R., Marzouk M. Synthesis and in vitro cytotoxicity evaluation of new 2-thioxo-benzo[g]quinazolin-4(3H)\u2013one derivatives. Heterocycles. 2015;91:1735\u20131751. doi: 10.3987/COM-15-13282.", "ArticleIdList": ["10.3987/COM-15-13282"]}, {"Citation": "Al-salahi R., Abuelizz H., Eldib R., Marzouk M. Antimicrobial of 2-Thioxo-benzo[g]quinazolin-4(3H)-one derivatives. Med. Chem. 2017;13:85\u201392. doi: 10.2174/1573406412666160610095706.", "ArticleIdList": ["10.2174/1573406412666160610095706", "27306606"]}, {"Citation": "Abuelizz H.A., El-Dib R.A., Marzouk M., Al-Salahi R. In vitro evaluation of new 2-phenoxy-benzo[g][1,2,4]triazolo[1,5-a]quinazoline derivatives as antimicrobial agents. Microbial Pathog. 2018;117:60\u201367. doi: 10.1016/j.micpath.2018.02.018.", "ArticleIdList": ["10.1016/j.micpath.2018.02.018", "29432912"]}, {"Citation": "Al-Salahi R., Moustapha M.E., Abuelizz H.A., Alharthi A.I., Alburikan K.A., Ibrahim I.T., Marzouk M., Motaleb M.A. Radioiodination and biodistribution of newly synthesized 3-benzyl-2-([3-methoxybenzyl]thio) benzo[g]quinazolin-4-(3H)-one in tumor bearing mice. Saudi Pharm. J. 2018;26:1120\u20131126. doi: 10.1016/j.jsps.2018.06.001.", "ArticleIdList": ["10.1016/j.jsps.2018.06.001", "PMC6260473", "30532632"]}, {"Citation": "Al-Salahi R., Ahmad R., ElHassane A., Marzouk M., Abuelizz H.A. 3-Benzyl(phenethyl)-2-thioxobenzo[g]quinazolines as a new class of potent \u03b1-glucosidase inhibitors: Synthesis and molecular docking study. Future Med. Chem. 2018;10:1889\u20131905. doi: 10.4155/fmc-2018-0141.", "ArticleIdList": ["10.4155/fmc-2018-0141", "29882426"]}, {"Citation": "Almehizia A.A., Abuelizz H.A., Taie H.A.A., ElHassane A., Marzouk M., Al-Salahi R. Investigation the antioxidant activity of benzo[g]triazolo quinazolines correlated with a DFT study. Saudi Pharm. J. 2019;27:133\u2013137. doi: 10.1016/j.jsps.2018.09.006.", "ArticleIdList": ["10.1016/j.jsps.2018.09.006", "PMC6323194", "30662316"]}, {"Citation": "Al-Salahi R., ElHassane A., Marzouk M., Abuelizz H.A. Anti-HAV evaluation and molecular docking of newly synthesized 3-benzyl(phenethyl)benzo[g]quinazolines. Bioorg. Med. Chem. Lett. 2019;29:1614\u20131619. doi: 10.1016/j.bmcl.2019.04.043.", "ArticleIdList": ["10.1016/j.bmcl.2019.04.043", "31054861"]}, {"Citation": "Al-Salahi R., Taie H.A.A., Bakheit A.H., Marzouk M., Almehizia A.A., Herqash R., Abuelizz H.A. Antioxidant activities and molecular docking of 2-thioxobenzo[g]quinazoline derivatives. Pharmacol. Rep. 2019;71:695\u2013700. doi: 10.1016/j.pharep.2019.04.003.", "ArticleIdList": ["10.1016/j.pharep.2019.04.003", "31207430"]}, {"Citation": "Nowak M., Malinowski Z., J\u00f3\u017awiak A.J., Fornal E., B\u0142aszczyk A., Kontek R. Substituted benzoquinazolinones. Part 1: Synthesis of 6-aminobenzo[h]quinazolinones via Buchwalde Hartwig amination from 6-bromobenzo[h]quinzolinones. Tetrahedron. 2014;70:5153\u20135160. doi: 10.1016/j.tet.2014.05.117.", "ArticleIdList": ["10.1016/j.tet.2014.05.117"]}, {"Citation": "Pendergast W., Dickerson S.H., Dev I.K., Ferone R., Duch D.S., Smith G.K. Benzo[flquinazoline inhibitors of thymidylate synthase: Methyleneamino-linked aroylglutamate derivatives. J. Med. Chem. 1994;37:838\u2013844. doi: 10.1021/jm00032a019.", "ArticleIdList": ["10.1021/jm00032a019", "8145235"]}, {"Citation": "Abuelizz H.A., Marzouk M., Bakheit A.H., Al-Salahi R. Investigation of some benzoquinazoline and quinazoline derivatives as novel inhibitors of HCV-NS3/4A protease: Biological, molecular docking and QSAR studies. RSC Adv. 2020;10:35820\u201335830. doi: 10.1039/D0RA05604A.", "ArticleIdList": ["10.1039/D0RA05604A", "PMC9056986", "35517076"]}, {"Citation": "Khodair A.I., Elsafi M.A., Al-Issa S.A. Simple and efficient synthesis of novel 3-substituted 2-thioxo-2,3-dihydro-1H-benzo[g]quinazolin-4-ones and their reactions with alkyl halides and \u03b1-glycolpy ranosyl bromides. J. Heterocycl. Chem. 2019;56:2358. doi: 10.1002/jhet.3623.", "ArticleIdList": ["10.1002/jhet.3623"]}, {"Citation": "Fallah A., Sadeghinia A., Kahroba H., Samadi A., Heidari H.R., Bradaran B., Zeinali S., Molavi O. Therapeutic targeting of angiogenesis molecular pathways in angiogenesis-dependent diseases. Biomed. Pharmacother. 2019;110:775\u2013785. doi: 10.1016/j.biopha.2018.12.022.", "ArticleIdList": ["10.1016/j.biopha.2018.12.022", "30554116"]}, {"Citation": "Wan J., Zhang L., Yang G., Zhan C.-G. Quantitative structure\u2212 activity relationship for cyclic imide derivatives of protoporphyrinogen oxidase inhibitors: A study of quantum chemical descriptors from density functional theory. J. Chem. Inf. Comput. Sci. 2004;44:2099\u20132105. doi: 10.1021/ci049793p.", "ArticleIdList": ["10.1021/ci049793p", "15554680"]}, {"Citation": "Kassem A.F., Nassar I.F., Abdel-Aal M.T., Awad H.M., El-Sayed W.A. Synthesis and anticancer activity of new ((Furan-2-yl)-1,3,4-thiadiazolyl)-1,3,4-oxadiazole acyclic sugar derivatives. Chem. Pharm. Bull. 2019;67:888\u2013895. doi: 10.1248/cpb.c19-00280.", "ArticleIdList": ["10.1248/cpb.c19-00280", "31366838"]}, {"Citation": "Abuelizz H.A., Awad A.M., Marzouk M., Nasr F.A., Bakheit A.H., Naglah A.M., Al-Salahi R. Exploiting the 4-Hydrazinobenzoic acid moiety for the development of anticancer agents: Synthesis and biological profile. Bioorg. Chem. 2020;102:104098. doi: 10.1016/j.bioorg.2020.104098.", "ArticleIdList": ["10.1016/j.bioorg.2020.104098", "32702510"]}, {"Citation": "Alminderej F.M., Elganzory H.H., El-Bayaa M.N., Awad H.M., El-Sayed W.A. Synthesis and cytotoxic activity of new 1,3,4-thiadiazole thiogl ycosides and 1,2,3-triazolyl-1,3,4-thiadiazole N-glycosides. Molecules. 2019;24:3738. doi: 10.3390/molecules24203738.", "ArticleIdList": ["10.3390/molecules24203738", "PMC6832760", "31623291"]}, {"Citation": "Alaaeldin G.M.F., Soltan M.M., Esam A.R., Hanna A.G. Synthesis and biological evaluation of novel 5-chloro-N-(4-sulfamoylbenzyl)salicylamide derivatives as tubulin polymerization inhibitors. MedChemComm. 2018;9:1511\u20131528.", "ArticleIdList": ["PMC6148682", "30288225"]}, {"Citation": "Barua A., Yellapa A., Bahr J.M., Machado S.A., Bitterman P., Basu S., Sharma S., Abramowicz J.S. VEGFR2-targeted ultrasound imaging agent anhances the detection of ovarian tumors at early stage in laying hens, a preclinical model of spontaneous ovarian cancer. Ultrasonic Imaging. 2015;37:224\u2013237. doi: 10.1177/0161734614553603.", "ArticleIdList": ["10.1177/0161734614553603", "25294846"]}, {"Citation": "Hasegawa K., Deushi T., Yoshida H., Miyashita Y., Sasaki S.I. Chemometric QSAR studies of antifungal azoxy compounds. J. Comput. Aided Mol. Des. 1994;8:449\u2013456. doi: 10.1007/BF00125379.", "ArticleIdList": ["10.1007/BF00125379", "7815096"]}, {"Citation": "Asadollahi T., Dadfarnia S., Shabani A.M.H., Ghasemi J.B., Sarkhosh M. QSAR models for CXCR2 receptor antagonists based on the genetic algorithm for data preprocessing prior to application of the PLS linear regression method and design of the new compounds using in silico virtual screening. Molecules. 2011;16:1928\u20131955. doi: 10.3390/molecules16031928.", "ArticleIdList": ["10.3390/molecules16031928", "PMC6259643", "21358586"]}, {"Citation": "Umar B.A., Uzairu A., Shallangwa G.A., Sani U. QSAR modeling for the prediction of pGI50 activity of compounds on LOX IMVI cell line and ligand-based design of potent compounds using in silico virtual screening. Netw. Modeling Anal. Health Inform. Bioinform. 2019;8:22. doi: 10.1007/s13721-019-0202-8.", "ArticleIdList": ["10.1007/s13721-019-0202-8"]}, {"Citation": "Veerasamy R., Rajak H., Jain A., Sivadasan S., Varghese C.P., Agrawal R.K. Validation of QSAR models-strategies and importance. Int. J. Drug Des. Discov. 2011;3:511\u2013519."}]}], "History": [{"Year": "2020", "Month": "11", "Day": "27"}, {"Year": "2020", "Month": "12", "Day": "12"}, {"Year": "2020", "Month": "12", "Day": "13"}, {"Year": "2020", "Month": "12", "Day": "18", "Hour": "1", "Minute": "2"}, {"Year": "2020", "Month": "12", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "9", "Day": "4", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "12", "Day": "15"}], "PublicationStatus": "epublish", "ArticleIdList": ["33333992", "PMC7765401", "10.3390/molecules25245944", "molecules25245944"]}}]}